Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events

• Published in: Cardiovascular diabetology Vol. 19; no. 1; pp. 46 - 15
• Main Authors: Spigoni, Valentina, Fantuzzi, Federica, Carubbi, Cecilia, Pozzi, Giulia, Masselli, Elena, Gobbi, Giuliana, Solini, Anna, Bonadonna, Riccardo C., Dei Cas, Alessandra
• Format: Journal Article
• Language: English
• Published: England BioMed Central 07.04.2020; BMC
• Subjects: Adenosine Diphosphate - pharmacology; Amiloride; Angiogenesis; Antidiabetics; Apoptosis; Apoptosis - drug effects; Arteriosclerosis; Atherosclerosis; Benzhydryl Compounds - pharmacology; Blood Platelets - drug effects; Blood Platelets - metabolism; Blood Platelets - pathology; Cell activation; Cell culture; Cells, Cultured; Cytometry; Diabetes; Diabetes mellitus (non-insulin dependent); Endothelial Progenitor Cells - drug effects; Endothelial Progenitor Cells - metabolism; Endothelial Progenitor Cells - pathology; Experiments; Gene expression; Glucosides - pharmacology; Heart failure; Humans; Inflammation Mediators - metabolism; Interleukin 1; Isoforms; Kidney diseases; Myeloid angiogenic cells; Na+/H+-exchanging ATPase; Original Investigation; Oxidants; Oxidative Stress - drug effects; PAC1 protein; Peripheral blood; Platelet Activation - drug effects; Platelets; SGLT-2 inhibitors; Signal Transduction; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 - metabolism; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Hydrogen Exchangers - metabolism; Sodium-proton exchanger; Stearic acid; Stearic Acids - toxicity; Superoxide dismutase; Thermal cycling; Thrombosis; Tumor necrosis factor-TNF; Tumor necrosis factor-α; United States > US; Italy; SGLT-2 inhibitors; Sodium-proton exchanger; Myeloid angiogenic cells; Platelets; Atherosclerosis

The clear evidence of cardiovascular benefits in cardiovascular outcome trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes might suggest an effect on atherosclerotic plaque vulnerability and/or thrombosis, in which myeloid angiogenic cells (MAC) and platelets (PLT) are i...